Reata’s Bardoxolone Shot Down, But US FDA Advisors Offer Suggestions For Improved Study

 
• By Sarah Karlin-Smith
  
healthy and chronic kidney diseased kidney
FDA advisors offered Reata a path forward for more studies of its chronic kidney disease drug. • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers